ReviewThe British journal of cancer. Supplement1992
Neuroblastoma in the very young child: biological considerations.
Review in The British journal of cancer. Supplement, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 6 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is one of the childhood malignancies that frustrates both the clinical and scientist. Clearly, some forms of the disease are relatively benign and the patient can expect to be cured. However, even today, Stage 4 neuroblastoma is one of the childhood malignancies where the overall prognosis remains very poor. Despite extensive investigations into the biology of the disease, little has been gleaned about the underlying causes of the tumour and what truly separates good and poor risk disease. Fortunately, patients under the age of one with neuroblastoma often fall into the good risk group. Many people now believe that neuroblastoma is not just one disease, but several. Some forms of the tumours may, in fact, not be truly malignant. The data that has led to this conclusion and the biological characteristics that are associated with the different forms of the neuroblastoma will be reviewed. In addition, a brief outline of new studies which may identify some of the factors associated with the neuroblasts ability to metastasise will be discussed.
Indexed as
Identifiers
1503919PMC2149661W160658965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.